Abvc Biopharma (ABVC) Liabilities and Shareholders Equity (2010 - 2026)

Abvc Biopharma (ABVC) has 16 years of Liabilities and Shareholders Equity data on file, last reported at $19.7 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 157.27% year-over-year to $19.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $69.7 million (up 124.54% YoY) and the FY2025 annual result came in at $21.1 million, up 179.34% from the prior year.
• Liabilities and Shareholders Equity eased to $19.7 million in Q1 2026, from $21.1 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $21.2 million in Q3 2025 to a low of $6.7 million in Q4 2023.
• A 5-year average of $11.6 million and a median of $9.6 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity tumbled 53.12% — and 2025, when it soared 179.34%.
• Tracing ABVC's Liabilities and Shareholders Equity over 5 years: stood at $9.6 million in 2022, then retreated by 29.97% to $6.7 million in 2023, then climbed by 12.4% to $7.5 million in 2024, then jumped by 179.34% to $21.1 million in 2025, then slipped by 6.31% to $19.7 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $19.7 million (Q1 2026), $21.1 million (Q4 2025), and $21.2 million (Q3 2025), per Business Quant data.